Evidence-Based Medicine Guidelines
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Systemic Safety of Bevacizumab Versus Ranibizumab for Neovascular Age-related Macular Degeneration." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/458377/all/Systemic_safety_of_bevacizumab_versus_ranibizumab_for_neovascular_age_related_macular_degeneration.
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. https://evidence.unboundmedicine.com/evidence/view/EBMG/458377/all/Systemic_safety_of_bevacizumab_versus_ranibizumab_for_neovascular_age_related_macular_degeneration. Accessed December 7, 2024.
Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. (2024). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/458377/all/Systemic_safety_of_bevacizumab_versus_ranibizumab_for_neovascular_age_related_macular_degeneration
Systemic Safety of Bevacizumab Versus Ranibizumab for Neovascular Age-related Macular Degeneration [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2024. [cited 2024 December 07]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/458377/all/Systemic_safety_of_bevacizumab_versus_ranibizumab_for_neovascular_age_related_macular_degeneration.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration
ID - 458377
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/458377/all/Systemic_safety_of_bevacizumab_versus_ranibizumab_for_neovascular_age_related_macular_degeneration
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
